AQR Capital Management LLC increased its holdings in Edwards Lifesciences Corp (NYSE:EW) by 7.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 975,154 shares of the medical research company’s stock after buying an additional 68,314 shares during the period. AQR Capital Management LLC owned 0.47% of Edwards Lifesciences worth $180,150,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Paloma Partners Management Co boosted its position in shares of Edwards Lifesciences by 35.2% in the second quarter. Paloma Partners Management Co now owns 205,033 shares of the medical research company’s stock worth $37,878,000 after purchasing an additional 53,337 shares during the period. Beacon Pointe Advisors LLC increased its stake in Edwards Lifesciences by 15.8% during the second quarter. Beacon Pointe Advisors LLC now owns 2,761 shares of the medical research company’s stock worth $512,000 after purchasing an additional 376 shares during the period. Capital Bank & Trust Co increased its stake in Edwards Lifesciences by 98,736.4% during the second quarter. Capital Bank & Trust Co now owns 65,232 shares of the medical research company’s stock worth $12,051,000 after purchasing an additional 65,166 shares during the period. Marshall Wace North America L.P. increased its stake in Edwards Lifesciences by 394.9% during the second quarter. Marshall Wace North America L.P. now owns 364,492 shares of the medical research company’s stock worth $67,336,000 after purchasing an additional 290,838 shares during the period. Finally, Balyasny Asset Management LLC increased its stake in Edwards Lifesciences by 134.8% during the second quarter. Balyasny Asset Management LLC now owns 13,922 shares of the medical research company’s stock worth $2,572,000 after purchasing an additional 53,922 shares during the period. Institutional investors own 81.53% of the company’s stock.
In other Edwards Lifesciences news, Director William J. Phd Link sold 10,214 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $221.86, for a total value of $2,266,078.04. Following the transaction, the director now owns 16,817 shares in the company, valued at $3,731,019.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 1,152 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $191.70, for a total value of $220,838.40. Following the completion of the transaction, the vice president now owns 19,162 shares in the company, valued at approximately $3,673,355.40. The disclosure for this sale can be found here. Insiders have sold 155,822 shares of company stock worth $33,641,784 over the last ninety days. 1.63% of the stock is owned by insiders.
Shares of EW traded up $1.02 during midday trading on Friday, reaching $227.11. The stock had a trading volume of 1,336,874 shares, compared to its average volume of 1,104,862. Edwards Lifesciences Corp has a 52 week low of $136.44 and a 52 week high of $230.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.38 and a quick ratio of 2.48. The firm’s 50 day moving average price is $219.92 and its 200-day moving average price is $197.32. The company has a market capitalization of $47.23 billion, a P/E ratio of 48.32, a P/E/G ratio of 2.83 and a beta of 0.84.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 EPS for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the business earned $1.24 EPS. The company’s quarterly revenue was up 15.2% compared to the same quarter last year. On average, equities analysts forecast that Edwards Lifesciences Corp will post 5.34 earnings per share for the current year.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Story: What is an inverted yield curve?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.